CRISPR RNPs and the Future of Cell and Gene Therapy
Download Article
| region | na1 |
| portalId | 1769030 |
| formId | 7d08e288-b33f-4e1c-bd5d-251262db95f1 |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you/crispr-rnps-and-the-future-of-cell-and-gene-therapy |
As clustered regularly interspaced short palindromic repeats (CRISPR) therapies progress to the clinic, the key CRISPR editing components are primarily being delivered by recombinant virus, RNA, or as ribonucleoprotein (RNP), which is the active complex formed by the guide RNA and Cas9 protein. RNPs have several attractive properties as a delivery format, particularly in the manufacturing of ex vivo cellular therapies, the most rapidly growing segment of the CRISPR therapeutics market.